Saisi Pengxin Biotechnology

Shenzhen Saisi Pengxin Biotechnology Co., Ltd. (Xpenarray) is a high-tech enterprise focused on developing and manufacturing in-vitro diagnostic (IVD) instruments and reagents. The company was founded in December 2015, with Han Di as the legal representative.

The firm specializes in liquid chip technology, also known as microsphere suspension array technology, a high-throughput diagnostic technique recognized by the U.S. FDA's expert committee as a future direction for in-vitro diagnostics. Xpenarray's product line includes five-category blood routine instruments, CRP detection instruments, and SAA detection instruments. The company's business model encompasses the research, development, technology transfer, and technical consulting for biotechnology, medical technology, and diagnostic and scientific research reagents and instruments. Revenue is generated from the production and sale of these medical devices.

The core team comprises serial entrepreneurs, executives from listed companies, and overseas returnees, with the R&D team possessing over 20 years of experience in the IVD field. The company has received multiple funding rounds, including an Angel round in March 2019 and a Series A in February 2018 from investors such as Puhua Capital and Kaiying Capital.

Keywords: in-vitro diagnostics, IVD, medical devices, liquid chip technology, microsphere suspension array, diagnostic reagents, biotechnology, medical technology, blood analysis instruments, CRP detection, SAA detection, high-throughput diagnostics, clinical laboratory, diagnostic technology, medical instruments